How high-density lipoprotein function is affected in patients with inflammatory muscle diseases
Official title: Altered High-Density Lipoprotein function in Patients with Idiopathic Inflammatory Myopathies
Funded at University of California Los Angeles · NIH-10908701 · Data updated 2026-11-12
This study is looking at how a type of good cholesterol called HDL, which usually helps keep your blood vessels healthy, doesn't work properly in people with idiopathic inflammatory myopathies (IIM), and it aims to find out why this happens and how it might lead to heart problems, so we can discover new ways to help.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $181,980 |
| NIH project number | 5K23AR081423-02 |
| Project ID | NIH-10908701 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic inflammatory myopathies.
✕Less likely to help
Patients with other autoimmune diseases not related to inflammatory myopathies may not benefit from this research.
What this research studies
This research investigates how high-density lipoproteins (HDL), which usually protect blood vessels, become dysfunctional in patients with idiopathic inflammatory myopathies (IIM). The study aims to understand the mechanisms behind vascular damage in these patients, particularly focusing on the role of HDL and its antioxidant properties. Researchers will explore the relationship between HDL function, inflammation, and the gut microbiome to identify potential therapeutic targets. By analyzing blood samples and gut microbiome profiles, the study seeks to uncover new insights into cardiovascular risks associated with IIM.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that protect against cardiovascular disease in patients with inflammatory muscle diseases.
How similar studies have gone: Previous research has shown promising results in understanding HDL dysfunction in other inflammatory conditions, suggesting potential for success in this novel approach.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Bae, Sangmee — University of California Los Angeles
- Study coordinator: Bae, Sangmee
Related research
Other NIH-funded projects on the same topics.
-
Immunophenotypes in inflammatory myopathies and linked lung disease
A physician-scientist at Vanderbilt is pursuing how immune cells and gene activity differ in Idiopathic Inflammatory Myopathies to find clues for better treatments.
-
Understanding Immune Differences in Muscle Inflammation
This project aims to understand the unique immune system features in people with idiopathic inflammatory myopathies to find better ways to help them.
-
Exploring how specific genetic elements contribute to autoimmune muscle diseases.
This study is looking at how certain genetic elements might cause muscle inflammation in people with autoimmune diseases that affect their muscles, and it hopes to find new ways to treat these conditions more effectively and with fewer side effects.
-
Investigating immune profiles in inflammatory muscle diseases
This study is looking at how the immune system affects muscle inflammation in people with idiopathic inflammatory myopathies (IIM) to find new ways to help improve treatment and care for patients like you.
-
MTS109 treatment for refractory autoimmune diseases
This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.
-
AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis
This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.